Home | MyCME | All CME | Blog | Psychlopedia

Current CME Activities

CME Activities From Our Journals

Online CME Activities

+From the series JCP CME Activities

Thomas E. Smith

Scheduling an outpatient mental health appointment is a widely recommended discharge planning practice, but little is known regarding how often this practice is followed or its effectiveness. Find answers in this journal CME activity.

Credits: 1.00 | Expires: 10/31/2022

Roel J. T. Mocking, Katja Steijn, Carolien Roos, Johanna Assies, Veerle Bergink, Henricus G. Ruhé, Aart H. Schene

JCP CME

Omega-3 Fatty Acid Supplementation for Perinatal Depression: A Meta-Analysis

When pregnant patients with a history of depression ask you about eating fish or using an omega-3 supplement, what do you tell them? Learn about research in the peripartum period in this journal CME activity.

Credits: 1.00 | Expires: 10/31/2022

Michelle J. Blumberg, Sophie R. Vaccarino, Shane J. McInerney

What is the efficacy of antidepressants and other agents for treating cognitive impairment in adults with major depressive disorder? Review available research in this CME journal activity.

Credits: 1.00 | Expires: 8/31/2022

Taeho Greg Rhee; Mark Olfson; Kyaw Sint; Samuel T. Wilkinson

JCP CME

Characterization of the Quality of Electroconvulsive Therapy Among Older Medicare Beneficiaries

How many older adults receive electroconvulsive therapy (ECT) for treatment-resistant depression? Among those who receive ECT, how many finish the course? What factors might predict patients’ continuation of ECT? Explore these topics in this journal CME activity.

Credits: 1.00 | Expires: 8/31/2022

Filipe Peste Martinho, Gonçalo Silva Duarte, Frederico Simões do Couto

First-line treatments for OCD include selective serotonin reuptake inhibitors and cognitive-behavioral therapy. But what do you do when patients do not respond to these or second-line strategies? In this journal CME activity, explore the option of deep brain stimulation.

Credits: 1.00 | Expires: 5/31/2022

Georgios Schoretsanitis, John M. Kane, Christoph U. Correll, Stephen R. Marder, Leslie Citrome, John W. Newcomer, Delbert G. Robinson, Donald C. Goff, Deanna L. Kelly, Oliver Freudenreich, Daria Piacentino, Michael Paulzen, Andreas Conca, Gerald Zernig, Ekkehard Haen, Pierre Baumann,  Christoph Hiemke, Gerhard Gründer, for the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrier

JCP CME

Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie

The quantification of antipsychotic levels in blood, or therapeutic drug monitoring (TDM), could aid clinicians in numerous challenging scenarios. Learn more about using TDM for dosing decisions in this journal CME activity that describes expert consensus.

Credits: 1.00 | Expires: 6/30/2022

Emily A. Ferenczi; Michael G. Erkkinen; Mel B. Feany; Barry S. Fogel; Kirk R. Daffner

JCP CME

New-Onset Delusions Heralding an Underlying Neurodegenerative Condition: A Case Report and Review of the Literature

In this CME journal article, the authors describe a case of new-onset psychosis in a middle-aged woman, review red-flags for a neurodegenerative diagnosis rather than a primary psychotic disorder, and examine the role of genetics.

Credits: 1.00 | Expires: 4/30/2022

Emil F. Coccaro, and Royce J. Lee

JCP CME

Disordered Aggression and Violence in the United States

Intermittent explosive disorder (IED) is associated with intimate partner assault, the use of weapons to threaten others, and arrests. This behavior can be reduced through pharmacologic and psychosocial interventions. Learn about IED in this CME journal article.

Credits: 1.00 | Expires: 4/30/2022

Jozefien M. Overbeek; Nicole Korten; Flora Gossink;
Jay Fieldhouse; Marleen van de Beek; Lianne Reus;
Annemieke Dols; Yolande Pijnenburg; and Sigfried Schouws

JCP CME

The Value of Neuropsychological Assessment in the Differentiation Between Behavioral Variant Frontotemporal Dementia and Late-Onset Psychiatric Disorders

How can you discriminate between behavioral variant frontotemporal dementia and psychiatric disorders with similar behavioral changes, such as apathy, disinhibition, reduced empathy, or compulsions? Which neuropsychological tests are useful?

Credits: 1.00 | Expires: 2/28/2022

Sara L. Johansen; Ben A. Stenhaug; Thalia K. Robakis; Katherine E. Williams; and Mark R. Cullen

JCP CME

Past Psychiatric Conditions as Risk Factors for Postpartum Depression: A Nationwide Cohort Study

What characteristics affect patients’ risk for postpartum depression? In what time frame is the risk greatest? Dr Johansen and colleagues analyzed a large US cohort to answer these questions. Find their results in this CME journal article.

Credits: 1.00 | Expires: 1/31/2022

Erica L. F. Buchalter; Hanadi Ajam Oughli; Eric J. Lenze;
David Dixon; J. Philip Millera; Daniel M. Blumberger;
Jordan F. Karp; Charles F. Reynolds III; and Benoit H. Mulsant

JCP CME

Predicting Remission in Late-Life Major Depression: A Clinical Algorithm Based Upon Past Treatment History

Rates of treatment resistance in randomized controlled trials in patients with late-life depression are as high as 77% using SSRIs, yet SSRIs are often used as first-line treatment. This CME article helps to optimize the selection of the next step in treating late-life depression.

Credits: 1.00 | Expires: 12/31/2021

Ty S. Schepis, and Sean Esteban McCabe

How does prescription opioid misuse affect people who are 50 years old and older? Are there standardized tools for assessment of misuse? What associated factors should clinicians look for when screening? Review this CME journal article for answers.

Credits: 1.00 | Expires: 11/30/2021

Amir Krivoy; Dan Joyce; Derek Tracy; Fiona Gaughran; James MacCabe; John Lally; Whiskey Eromona; S. Neil Sarkar, and Sukhwinder S. Shergill

JCP CME

Real-World Outcomes in the Management of Refractory Psychosis

Clozapine is the only medication approved for refractory schizophrenia, yet it is underused. Further, for minimal response to clozapine treatment, there is little guidance on the next step. Here, review outcomes data for inpatients with refractory psychosis.

Credits: 1.00 | Expires: 10/31/2021

Sally Mustafa; Ridha Joober; Srividya Iyer; Jai Shah; Martin Lepage; Ashok Malla

When does antipsychotic-induced weight gain occur? Are preventive interventions warranted at the time of antipsychotic initiation in medication-naïve, first-episode patients?

Credits: 1.00 | Expires: 9/30/2021

Christine Li; Boris Birmaher; Brian Rooks; Mary Kay Gill; Heather Hower; David A. Axelson; Daniel P. Dickstein, MD; Tina R. Goldstein; Fangzi Liao; Shirley Yen; Jeffrey Hunt; Satish Iyengar; Neal D. Ryan; Michael A. Strober; Martin B. Keller; and Benjamin I. Goldstein

JCP CME

High Prevalence of Metabolic Syndrome Among Adolescents and Young Adults With Bipolar Disorder

Credits: 1.00 | Expires: 8/31/2021

Sophie Grigoriadis; Lisa Graves; Miki Peer; Lana Mamisashvili; Cindy-Lee Dennis; Simone N. Vigod; Meir Steiner; Cara Brown; Amy Cheung; Hiltrud Dawson; Neil Rector; Melanie Guenette; and Margaret Richter

JCP CME

Benzodiazepine Use During Pregnancy Alone or in Combination With an Antidepressant and Congenital Malformations: Systematic Review and Meta-Analysis

Is prenatal benzodiazepine use associated with an increased risk of congenital malformations? What about concurrent use of a benzodiazepine and an antidepressant? Does the trimester have an effect? See what these reviewers found.

Credits: 1.00 | Expires: 8/30/2021

Dara E. Babinski, Daniel A. Waschbusch, and James G. Waxmonsky

Despite the high risk for depression, not all youth with ADHD develop a mood disorder. Which children are at highest risk? How does early or late puberty affect the risk?

Credits: 1.00 | Expires: 6/30/2022

Mark Olfson, Carlos Blanco, Melanie M. Wall, Shang-Min Liu, and Bridget F. Grant

When patients present for treatment of anxiety or mood disorders, do you consider whether there is also an untreated substance use disorder? Check out these data on disorder prevalence and treatment rates.

Credits: 1.00 | Expires: 6/30/2021

Roger D. Weiss, Margaret L. Griffin, David E. Marcovitz, Blake T. Hilton, Garrett M. Fitzmaurice, R. Kathryn McHugh, and Kathleen M. Carroll

JCP CME

Correlates of Opioid Abstinence in a 42-Month Posttreatment Naturalistic Follow-Up Study of Prescription Opioid Dependence

Which treatments are strongly associated with opioid abstinence over time among patients with prescription opioid dependence: Opioid agonists? Outpatient counseling? Mutual-help group attendance?

Credits: 1.00 | Expires: 4/30/2021

Mu-Hong Chen, Han-Ting Wei, Ya-Mei Bai, Kai-Lin Huang, Nai-Ying Ko, Tung-Ping Su, Cheng-Ta Li, Wei-Chen Lin, Shih-Jen Tsai, Tzeng-Ji Chen, and Ju-Wei Hsu

JCP CME

Sexually Transmitted Infection Among Adolescents and Young Adults With Bipolar Disorder: A Nationwide Longitudinal Study

What are some risk factors for (and protective factors against) sexually transmitted infections among adolescents and young adults with bipolar disorder?

Credits: 1.00 | Expires: 3/31/2021

Eric T. Dobson, Michael H. Bloch, and Jeffrey R. Strawn

Medications can reduce anxiety in children and adolescents, but treatment response, tolerability, and treatment-emergent suicidality differ among these medications and medication classes. Read this journal CME article to learn about meta-analysis results.

Credits: 1.00 | Expires: 2/28/2021

David Misdrahi, Arnaud Tessier, Antoine Daubigney, Wassilios G. Meissner, Franck Schurhoff, Laurent Boyer, Ophélia Godin, Ewa Bulzacka, Bruno Aouizerate, Meja Andrianarisoa, Fabrice Berna, Delphine Capdevielle, Isabelle Chereau-Boudet, Thierry D’Amato, Caroline Dubertret, Julien Dubreucq, Catherine Faget-Agius, Christophe Lançon, Jasmina Mallet, Christine Passerieux, Romain Rey, Aurélie Schandrin, Mathieu Urbach, Pierre Vidailhet, Pierre-Michel Llorca, and Guillaume Fond for the FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Group

JCP CME

Prevalence of and Risk Factors for Extrapyramidal Side Effects of Antipsychotics: Results From the National FACE-SZ Cohort

When you see patients taking antipsychotics, do you systematically evaluate them for extrapyramidal side effects? Read this CME journal article for data on risk factors associated with drug-induced parkinsonism and tardive dyskinesia.

Credits: 1.00 | Expires: 2/28/2021

Soham Rej, Nathan Herrmann, Andrea Gruneir, Racquel Jandoc, Eric McArthur, Stephanie Dixon, and Amit X. Garg

JCP CME

Blood Lithium Monitoring Practices in a Population-Based Sample of Older Adults

Do you have older patients who are taking lithium? If so, have you checked the recommended frequencies for blood monitoring in older adults? Read this journal CME article to find out about appropriate laboratory monitoring.

Credits: 1.00 | Expires: 12/31/2020

Brian Shiner, Christine Leonard Westgate, Jiang Gui, Shira Maguen, Yinong Young-Xu, Paula P. Schnurr, and Bradley V. Watts

JCP CME

A Retrospective Comparative Effectiveness Study of Medications for Posttraumatic Stress Disorder in Routine Practice

How do treatments for posttraumatic stress disorder (PTSD) compare in routine clinical practice? Read this CME retrospective study of patient records for a look at real-life outcomes. Patients were taking fluoxetine, paroxetine, sertraline, topiramate, or venlafaxine, and some had concurrent psychotherapy.

Credits: 1.00 | Expires: 10/31/2020

+From the series JCP Fundamentals: Getting Back to the Basics Diagnosing, Treating, and Educating Patients With Tardive Dyskinesia

Supported by an educational grant from Neurocrine Biosciences, Inc.

+From the series TESTING

+From the series Recognizing and Treating Excessive Daytime Sleepiness in Patients With Narcolepsy

Supported by an educational grant from Harmony Biosciences, LLC.

Thomas Roth, PhD

Individuals with narcolepsy may experience not only academic, social, and occupational consequences but also dangerous driving or other accidents, meaning that effective treatment is critical. Here, review the evidence on treatment strategies.

Credits: 0.50 | Expires: 8/31/2022

John W. Winkelman, MD, PhD

Which patients need evaluation for excessive daytime sleepiness and central hypersomnias? How do the diagnoses of narcolepsy type 1 and type 2 differ? Dr Winkelman shares his expertise in this brief CME activity.

Credits: 0.50 | Expires: 7/31/2022

+From the series Dementia-Related Psychosis: Recognition and Treatment

Supported by an educational grant from ACADIA Pharmaceuticals Inc.

Dag Aarsland, MD, PhD

What is the impact of psychotic symptoms on patients with dementia and their care partners? Do you discuss delusions and hallucinations with them? Do you use assessment tools and evidence-based therapeutic strategies? Work your way through this series of engaging CME activities to learn from experts about recognizing and managing dementia-related psychosis.

Credits: 0.50 | Expires: 9/30/2022

+From the series PCC CME Activities

La Vonne Ann Downey and Les Zun

PCC CME

Who Has the Ability to Consent?

Does the capacity to consent vary between medical and psychiatric patients? Are tools needed to assess the patient’s decision-making capacity, or can the provider’s assessment be relied upon? Review the results of a study that sought answers to these questions in this CME journal activity.

Credits: 1.00 | Expires: 8/31/2022

Anh-Vu Nguyen, Keith A. Young, James A. Bourgeois

In addition to psychosis, depressive symptoms can occur in patients with anti-NMDAR encephalopathy (ANMDARE). ANDMARE should be considered in patients presenting with psychotic or atypical depressive illnesses. Early recognition of ANMDARE could lead to better management of this potentially life-threatening autoimmune disorder.

Credits: 1.00 | Expires: 7/31/2022

João Gama Marques

Patients with psychosis are too often diagnosed with primary schizophrenia when the psychotic symptoms may actually be the manifestation of neurologic, endocrine, or immunologic disease. Learn about alternate diagnoses in this CME journal article.

Credits: 1.00 | Expires: 4/30/2022

Lauren T. Perlis; J. Steven Lamberti; and Susanne U. Miedlich

Certain antipsychotics are known to increase weight and the risk for diabetes. Could some medications for diabetes promote not only glycemic control but also weight loss in patients taking antipsychotics? In this CME activity, review the results of a small retrospective study.

Credits: 1.00 | Expires: 2/28/2022

Ermal Bojdani, Anderson Chen, Tina Zhang, Nida Naqvi, Dil Tahera

PCC CME

Hypertensive Urgency and Emergency in Alcohol Withdrawal: A Literature Review

Data are lacking on how best to manage hypertension in patients experiencing alcohol withdrawal. Dr Bojdani and colleagues offer strategies for addressing hypertension in patients detoxifying from alcohol.

Credits: 1.00 | Expires: 12/31/2021

Po-Heng Tsai, Gurmehr Kaur, Ganesh Gopalakrishna

How do you proceed when a patient younger than 65 presents with cognitive complaints? Early-onset Alzheimer’s disease may not appear in the typical presentation that you expect from AD. Follow along with this case from experts at Banner Alzheimer’s Institute.

Credits: 1.00 | Expires: 10/31/2021

Keri Hager; Margarette Kading; Carolyn O’Donnell; Ann Yapel; Danielle MacDonald; Jennifer Nelson Albee; Cynthia Nash; Colleen Renier; Katherine Dean; and Mark Schneiderhan

PCC CME

Bridging Community Mental Health and Primary Care to Improve Medication Monitoring and Outcomes for Patients With Mental Illness Taking Second-Generation Antipsychotics—HDC/DFMC Bridge Project, Phase 1: Group Concept Mapping

Care coordination across health systems is critical to optimize patient care for chronic medical and psychiatric conditions. Group concept mapping provides a strategic process to allow shared-decision making among stakeholders.

Credits: 1.00 | Expires: 8/31/2021

Ivan Netto, Vivek H. Phutane, and Bipin Ravindran

Lithium neurotoxicity, both reversible and irreversible, can occur when lithium is combined with second-generation antipsychotics. Early detection and prompt management are needed. Do you know the causative factors?

Credits: 1.00 | Expires: 6/30/2022

Lorig K. Kachadourian, Ilan Harpaz-Rotem, Jack Tsai, Steven M. Southwick, and Robert H. Pietrzak

PCC CME

Posttraumatic Stress Disorder Symptoms, Functioning, and Suicidal Ideation in US Military Veterans: A Symptomics Approach

How would you use a symptom-focused approach to provide a more nuanced method for the assessment, monitoring, and treatment of PTSD?

Credits: 1.00 | Expires: 4/30/2021

Matthew A. Schreiber, Stephanie C. Armstrong, and Jesse D. Markman

PCC CME

Psychotropic Medication Monitoring: A Review

Psychotropic medications provide therapeutic benefits but also carry iatrogenic risks. Medication monitoring helps minimize this risk. This CME journal article offers clinicians a review of guidelines and presents monitoring recommendations with a convenient 1-page quick guide.

Credits: 1.00 | Expires: 2/28/2021

Mohan Gautam and Deepak Prabhakar

Various formulations of methylphenidate and amphetamine are approved for the treatment of attention-deficit/hyperactivity disorder (ADHD). The drug delivery mechanisms of these compounds create unique parameters that differ considerably among the formulations. This CME article is a comprehensive guide for prescribing clinicians.

Credits: 1.00 | Expires: 12/31/2020

Gloria Martz, William Tankersley, Hema Madhuri Mekala, and Huda Motiwala, MD

PCC CME

Rates of Synthetic Cannabinoid Use in Adolescents Admitted to a Treatment Facility

What do you know about the use of synthetic marijuana among adolescents? Read this CME article to learn about why they use it, what the risks are, and whether they perceive it as dangerous.

Credits: 1.00 | Expires: 10/31/2020

+From the series The Schizophrenia Remission Roller Coaster: Using Long-Acting Injectable Antipsychotics to Improve Adherence and Enhance Potential for Functional Recovery

Supported by educational grants from Alkermes, Inc., Otsuka America Pharmaceutical, Inc. and Lundbeck.

Christoph U. Correll, MD, and John Lauriello, MD

In this journal CME activity, find experts’ recommendations for reducing schizophrenia relapse, such as adopting a patient-centered approach, selecting medications based on current evidence, and implementing psychosocial interventions.

Credits: 1.00 | Expires: 8/31/2022

John Lauriello, MD

You can help your patients with schizophrenia achieve the ultimate goal of treatment—recovery. Learn how to use patient-centered care to enhance medication adherence and aid functional recovery.

Credits: 0.50 | Expires: 4/30/2022

Christoph U. Correll, MD

New treatments for schizophrenia may improve symptom domains other than positive symptoms and reduce adverse effects. Here, an expert summarizes data on approved and investigational agents.

Credits: 1.00 | Expires: 3/31/2022

Christoph U. Correll, MD

Patient-reported outcomes are important for assessing the impact of schizophrenia and the success of treatment. Dr Correll discusses patient-centered care.

Credits: 1.00 | Expires: 3/31/2022

John Lauriello, MD

What can you do to combat relapse in your patients with schizophrenia? Dr Lauriello discusses identifying and addressing a major contributor to relapse—nonadherence to antipsychotics.

Credits: 0.50 | Expires: 3/31/2022

+From the series Identifying and Treating Insomnia in Patients Living with Alzheimer’s Disease

Supported by an educational grant from Merck & Co, Inc.

Alon Y. Avidan, MD, MPH, and Anna D. Burke, MD

Webcast

Identifying and Treating Insomnia in Patients Living with Alzheimer’s Disease

For people living with Alzheimer's disease, sleep disturbances are often problematic for the patient and their family. In this CME webcast, watch short videos to gain insight from experts into the recognition and treatment of insomnia in these patients.

Credits: 1.75 | Expires: 4/30/2022

+From the series Revisiting Tardive Dyskinesia: Focusing on the Basics of Identification and Treatment

Supported by an educational grant from Teva Pharmaceuticals.

Leslie Citrome, MD, MPH, and Stephen R. Saklad, PharmD, BCPP

JCP CME

Revisiting Tardive Dyskinesia: Focusing on the Basics of Identification and Treatment

What should you rule out to diagnose tardive dyskinesia (TD)? How do treatment options differ? In this journal CME activity, Drs Citrome and Saklad team up to review the best clinical strategies.

Credits: 1.00 | Expires: 4/30/2022

Leslie L. Citrome, MD, MPH

After so many years of having inadequate treatment options, you can finally offer patients with tardive dyskinesia approved medications that reduce symptoms. Follow along as expert Dr Leslie Citrome reviews the evidence.

Credits: 0.50 | Expires: 1/31/2022

Stephen R. Saklad, PharmD, BCPP

Tardive dyskinesia must be detected early to minimize the risk of permanence. Do you know how often to screen patients and how to conduct an evaluation? Dr Stephen Saklad provides a refresher in this brief CME activity.

Credits: 0.50 | Expires: 12/31/2021

+From the series Early Recognition and Treatment of Tardive Dyskinesia in Patients With Mood Disorders and Schizophrenia

Supported by an educational grant from Neurocrine Biosciences, Inc.

Joseph P. McEvoy, MD, and Daniel E. Kremens, MD, JD

Review highlights from 2 experts’ presentations on identifying and treating tardive dyskinesia (TD). Quotes from actual patients with TD illustrate the embarrassment that they feel and show why even mild movements should be treated if patients are distressed by them.

Credits: 1.00 | Expires: 2/28/2022

Daniel E. Kremens, MD, JD

Brief Report

Treatment Strategies for Tardive Dyskinesia

What steps do you take when patients exhibit tardive dyskinesia? Are you familiar with treatment guidelines and data on approved and non-approved strategies? Explore recommendations from Dr Daniel Kremens.

Credits: 0.50 | Expires: 11/30/2021

Daniel E. Kremens, MD, JD

Brief Report

Earlier Diagnosis of Tardive Dyskinesia

Do you proactively assess patients for tardive dyskinesia? Here, learn about screening and diagnosis from an expert.

Credits: 0.50 | Expires: 11/30/2021

Joseph P. McEvoy, MD

Two medications are FDA-approved to treat tardive dyskinesia, and new long-term evidence has been reported. Follow along as expert Joseph P. McEvoy, MD, reviews the evidence.

Credits: 0.50 | Expires: 11/30/2021

Joseph P. McEvoy, MD

How does tardive dyskinesia affect patients' work and relationships? Should TD be treated even if patients lack insight into its presence? Dr Joseph McEvoy considers these questions and more in this brief CME activity.

Credits: 0.50 | Expires: 10/31/2021

+From the series Measurement-Based Care for Depression From Screening and Assessment Through Treatment

Supported by an educational grant from the University of Texas Southwestern Medical Center.

Madhukar H. Trivedi, MD

When you are treating a patient for depression, do you regularly assess symptoms, adherence, and side effects using tools and then use that information to guide treatment decisions? Learn from an expert about how measurement-based care will help you improve depression outcomes.

Credits: 0.50 | Expires: 3/31/2022

Madhukar H. Trivedi, MD

Identification of depression is crucial, as untreated depression is linked to functional impairment and suicide. Learn from an expert about how measurement-based care provides a way to improve the recognition of depression and comorbid conditions.

Credits: 0.50 | Expires: 3/31/2022

+From the series Earlier Diagnosis and Expanded Treatment Options for Patients With Parkinson Disease

Supported by an educational grant from Biogen MA, Inc.; Lundbeck LLC; and Sunovion Pharmaceuticals, Inc

Stuart H. Isaacson, MD

Which medications can improve the various motor and nonmotor symptoms of Parkinson disease? Dr Isaacson offers strategies to address multiple challenges posed by the illness.

Credits: 1.00 | Expires: 12/31/2021

Stuart H. Isaacson, MD

What are the cardinal features of Parkinson disease? What other motor and nonmotor symptoms do patients experience? Dr Isaacson describes diagnostic criteria and assessment tools.

Credits: 0.50 | Expires: 12/31/2021

+From the series Strategies for Acute and Maintenance Treatment of Bipolar I Disorder

Supported by an educational grant from Otsuka America Pharmaceutical, Inc., and Lundbeck.

Trisha Suppes, MD, PhD

Guidelines lay out strategies for maintenance treatment of bipolar I disorder, with an algorithm for pharmacologic and psychosocial interventions. Dr Suppes describes guideline recommendations and situations when you might need to vary from the algorithm.

Credits: 0.50 | Expires: 12/31/2021

Trisha Suppes, MD, PhD

When should you rely on top-ranked treatment options for acute bipolar mania, and when should you skip down to lower-ranked options? In this brief CME activity, expert Dr Suppes describes guideline recommendations and provides a case illustration.

Credits: 0.50 | Expires: 12/31/2021

+From the series A Multidisciplinary Approach for Addressing Challenges in Alzheimer’s Disease

Supported by educational grants from ACADIA Pharmaceuticals Inc.; Allergan; Avanir Pharmaceuticals, Inc.; and Biogen MA, Inc.

Alireza Atri, MD, PhD (Chair); Danielle Goldfarb, MD; Simon Sheard, DO; and Lynn Shaughnessy, PsyD

JCP CME

Current and Emerging Solutions to Challenges in the Management of Alzheimer’s Disease

Learn from experts in neurology, psychiatry, neuropsychology, and primary care about working with patients and care partners to create management plans for Alzheimer’s disease that ensure safety, optimize patient autonomy, and minimize agitation and conflict.

Credits: 1.00 | Expires: 12/31/2021

Alireza Atri, MD, PhD; Simon Sheard, DO; and Danielle Goldfarb, MD

Webcast

A Multidisciplinary Approach for Addressing Challenges in Alzheimer's Disease

In a series of brief video segments, experts in neurology, psychiatry, and primary care discuss the diagnosis and treatment of Alzheimer’s disease.

Credits: 1.00 | Expires: 8/31/2021

Lynn Shaughnessy, PsyD; Simon Sheard, DO; Danielle Goldfarb, MD; and Alireza Atri, MD, PhD

Brief Report

Cognitive Assessment of Alzheimer’s Disease and Dementias in Clinical Practice: Pragmatics of Brief Instruments and Neuropsychological Evaluation

Meaningful benefits can be derived from the evaluation of cognition in older adults when there is possible cognitive impairment and dementia. In this CME activity, experts explain how brief cognitive assessment tools and neuropsychological evaluations can aid diagnosis and inform a management plan.

Credits: 1.50 | Expires: 6/30/2021

Danielle Goldfarb, MD; Simon Sheard, DO; Lynn Shaughnessy, PsyD; and Alireza Atri, MD, PhD

Brief Report

Disclosure of Alzheimer’s Disease and Dementia: Patient- and Care Partner-Centric Decision-Making and Communication

Disclosing a diagnosis of dementia can be one of the most challenging aspects of care for clinicians. But doing so in a timely fashion benefits patients and their care partners. In this CME activity, learn about using patient-centered communication and following a structured process to disclose the diagnosis.

Credits: 1.00 | Expires: 2/28/2021

+From the series Hands-On TMS Symposium 2019

Supported by TMS Health Solutions.

In-kind support provided by Brainsway, Magstim, MagVenture, and Neuronetics.

+From the series Optimizing Treatment Choices to Improve Adherence and Outcomes in Schizophrenia

Supported by an educational grant from Indivior Inc.

John M. Kane, MD, and Christoph U. Correll, MD

JCP CME

Optimizing Treatment Choices to Improve Adherence and Outcomes in Schizophrenia

Long-acting injectable antipsychotics can be a powerful strategy in helping patients to receive ongoing benefit from treatment. You might think that you have adequately explained this treatment option to patients, but they may not have understood. How can communication be improved? See this Academic Highlights to find out.

Credits: 1.00 | Expires: 10/31/2021

+From the series New Mechanisms, New Opportunities: Integrating Novel Antidepressants in the Treatment of Major Depressive Disorder

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck.

Leslie Citrome, MD, MPH; James W. Murrough, MD, PhD; Joseph F. Goldberg, MD; Bradley N. Gaynes, MD, MPH; and Terence Ketter, MD

Audio Summary

New Mechanisms, New Opportunities: Integrating Novel Antidepressants in the Treatment of Major Depressive Disorder

New mechanisms of action present new opportunities to improve outcomes for patients with depression. Listen to a panel of experts discuss best practices and novel antidepressants at the 2019 ASCP Annual Meeting.

Credits: 1.50 | Expires: 7/31/2021

+From the series Managing Transitions in Care and Adherence to Improve Outcomes in Schizophrenia

Supported by an educational grant from Alkermes, Inc.

John Lauriello, MD, and Diana O. Perkins, MD

Relapse of schizophrenia often occurs due to treatment nonadherence. Long-acting injectable (LAI) antipsychotics can improve adherence but are underused. Watch this Webcast to hear interviews with patients and learn from experts how LAIs may translate into clinical benefit.

Credits: 2.00 | Expires: 3/31/2021

John Lauriello, MD, and Diana O. Perkins, MD

Interruptions in treatment increase the risk of relapse in patients with schizophrenia. Read this Academic Highlights activity to learn about factors that contribute to nonadherence, effective methods for monitoring adherence, and strategies for ensuring continuous treatment.

Credits: 1.00 | Expires: 2/28/2021

+From the series Overcoming Challenges in Diagnosis and Depression Management in Pediatric Bipolar Disorder

Supported by an educational grant from Sunovion Pharmaceuticals, Inc.

Melissa P. DelBello, MD, MS

Children whose bipolar disorder is inadequately treated often grow into adults who are unable to manage their illness. Read this Brief Report to discover the most effective treatment strategies to help patients and families learn to control and cope with their bipolar disorder, particularly episodes of depression, as they advance towards adulthood.

Credits: 0.50 | Expires: 12/31/2020

Manpreet K. Singh, MD, MS

At least half of the cases of bipolar disorder begin in childhood or adolescence. How do you decide whether a young patient's symptoms indicate bipolar disorder? Read this CME Brief Report to learn about reliable tools and methods to identify bipolar disorder in pediatric patients.

Credits: 0.50 | Expires: 12/31/2020

+From the series Migraine Headache: Diagnosis and Current and Emerging Preventive Treatments

Supported by an educational grant from Lilly.

Richard B. Lipton, MD, and Stephen Silberstein, MD

Journal Supplement

Migraine Headache: Diagnosis and Current and Emerging Preventive Treatments

Most people with primary headache disorders, such as migraine, are undiagnosed. Read this PCC Supplement for updated classifications and assessments for patients with headache disorders and ways to identify and educate patients who are candidates for preventive treatment.

Credits: 1.00 | Expires: 12/31/2020

+From the series Current and Emerging Treatments to Address Unmet Needs in MDD

Supported by an educational grant from Alkermes, Inc.

Michael E. Thase, MD

Most people who experience a depressive episode are greatly impaired by it. No one-size-fits-all therapy is available, and most patients require multiple treatment steps. Check out this CME activity to learn about current and emerging strategies for managing MDD.

Credits: 1.00 | Expires: 12/31/2020

+From the series Getting to Remission: Differentiating Residual Symptoms From Treatment Side Effects in Major Depressive Disorder

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck.

+From the series Effective Management Approaches for Psychosis in Patients With Parkinson Disease

Supported by an educational grant from Acadia Pharmaceuticals Inc.

Rajesh Pahwa, MD (Chair), and Daniel E. Kremens, MD, JD

Journal Supplement

Effective Management Approaches for Psychosis in Patients With Parkinson Disease

Are you familiar with diagnostic criteria for Parkinson disease psychosis (PDP)? Do you know which psychotic symptoms occur in the majority of patients with PD? Read this CME supplement by 2 experts in the field for an update on PDP symptoms and treatments.

Credits: 1.00 | Expires: 9/30/2020

+From the series Improving the Diagnosis and Treatment of Adolescent Bipolar Disorder

Supported by an educational grant from Sunovion Pharmaceuticals Inc.

Robert L. Findling, MD, MBA

Brief Report

Treating Bipolar Disorder in Adolescents

How do you select among treatments for bipolar disorder in adolescents? Check out this brief report activity to explore the efficacy and safety of lithium, anticonvulsants, and atypical antipsychotics in the treatment of adolescent bipolar disorder. Plus, receive guidance for monitoring for common adverse effects, such as weight gain and fatigue.

Credits: 0.50 | Expires: 1/31/2021

Kiki D. Chang, MD

As many as 2 million youths in the US alone could have bipolar disorder. In this CME brief report, get up-to-date on common presentations of pediatric bipolar disorder, DSM-5 diagnostic criteria, and structured interviews and screening tools that can help you detect manic symptomatology.

Credits: 0.50 | Expires: 1/31/2021

+From the series Tardive Dyskinesia: Recognition, Patient Assessment, and Differential Diagnosis

Supported by an educational grant from Neurocrine Biosciences, Inc.

+From the series Parkinson Disease: Current Trends in Treatment and Unmet Needs

Independently developed by the CME Institute of Physicians Postgraduate Press, Inc.

+From the series Reconsidering Insomnia as a Disorder Rather Than Just a Symptom in Psychiatric Practice

Supported by an educational grant from Merck & Co., Inc.

+From the series Cognitive Impairment in Patients With Depression: Awareness, Assessment, and Management

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck.

Larry Culpepper, MD, MPH

Pronounced deficits in executive function are found in up to one-third of patients with MDD, and this impairment can keep patients from achieving full functional recovery. In this CME activity, review the evidence regarding the effectiveness of available interventions to improve cognitive dysfunction in patients with MDD. "

Credits: 0.50 | Expires: 10/31/2020

+From the series Long-Acting Injectable Antipsychotics: Where Do They Fit in the Treatment Plan?

Supported by an educational grant from Alkermes, Inc.

+From the series What You Should Know About Tardive Dyskinesia: Screening, Causes, and New Treatment Options

Supported by an educational grant from Neurocrine Biosciences, Inc.

+From the series Remove

+From the series Improving Remission Rates in Major Depressive Disorder: A Case-Based Approach

Supported by an educational grant from Otsuka America Pharmaceutical Inc. and Lundbeck. Brought to you through the joint providership of the CME Institute of Physicians Postgraduate Press, Inc., Medical Education Resources, and CMEology.

+From the series Emerging Treatment Strategies for Patients With Tardive Dyskinesia

Supported by an educational grant from Teva Pharmaceuticals.

Christoph U. Correll, MD (Chair); John M. Kane, MD; and Leslie L. Citrome, MD, MPH

JCP CME

Epidemiology, Prevention, and Assessment of Tardive Dyskinesia and Advances in Treatment

Is your patient experiencing involuntary movements of the face, torso, or extremities? It could be tardive dyskinesia, a side effect of antipsychotic medications. Explore this CME Academic Highlights activity to find out who’s at risk for developing tardive dyskinesia and how it can be prevented. Plus, learn about assessment strategies and tools as well as evidence for treatments.

Credits: 1.00 | Expires: 10/31/2020

+From the series Improving Long-Term Outcomes in Patients With Schizophrenia: What Is the Evidence for Long-Acting Injectable Antipsychotics?

Supported by an educational grant from Otsuka America Pharmaceutical Inc. and Lundbeck. Brought to you through the joint providership of the CME Institute of Physicians Postgraduate Press, Inc., Medical Education Resources, and CMEology.

+From the series Diagnosing and Treating Patients With Mixed Features

Supported by an educational grant from Sunovion Pharmaceuticals Inc.

+From the series Advanced Topics in Major Depressive Disorder: Practical Strategies to Improve Remission

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck. Brought to you through the joint providership of the CME Institute of Physicians Postgraduate Press, Inc., and CMEology.

+From the series Challenges in the Recognition and Treatment of Binge-Eating Disorder

This Supplement is derived from the planning teleconference series “Challenges in the Recognition and Treatment of Binge-Eating Disorder,” which was held in May, June, and July 2016, and was independently developed by the CME Institute of Physicians Postgraduate Press, Inc., pursuant to an educational grant from Shire.

+From the series Recognition and Treatment of Pediatric Bipolar Disorder

This Supplement is derived from the planning teleconference series “Recognition and Treatment of Pediatric Bipolar Disorder,” which was held in August and September 2015, and was independently developed by the CME Institute of Physicians Postgraduate Press, Inc., pursuant to an educational grant from Forest Laboratories, Inc.

+From the series Improving the Care and Management of Patients With Inadequate Response to Depression Treatment

Supported by an educational grant from Otsuka Pharmaceutical Development and Commercialization, Inc.

+From the series Enhancing Approaches to the Identification and Management of Pseudobulbar Affect

Supported by an educational grant from Otsuka America Pharmaceutical, Inc. Brought to you through the joint providership of the CME Institute of Physicians Postgraduate Press, Inc., and CMEology.

+From the series Achieving Remission and Recovery in Depression With Anxiety

Supported by an educational grant from Forest Laboratories, Inc.

+From the series Measuring and Managing Cognitive Impairment in Schizophrenia

This Supplement is derived from the planning teleconference series “Measuring and Managing Cognitive Impairment in Schizophrenia,” which was held in April and May 2015 and was independently developed by the CME Institute of Physicians Postgraduate Press, Inc., pursuant to an educational grant from FORUM Pharmaceuticals.

+From the series Sleep Disorders in the Psychiatric Setting

Supported by an educational grant from Merck.

+From the series Strategies to Improve Outcomes for Primary Care Patients With Major Depressive Disorder

Supported by an educational grant from Takeda Pharmaceuticals International, Inc., U.S. Region and Lundbeck.

+From the series Recognizing and Treating Excessive Daytime Sleepiness and Narcolepsy

Supported by an educational grant from Jazz Pharmaceuticals.

+From the series Complicated Major Depressive Disorder

Suppported by educational grants from Eli Lilly and Company and Bristol-Myer Squibb Company and Otsuka America Pharmaceutical, Inc.

+From the series What Psychiatric Nurses Need to Know About Bipolar Disorder

Supported by an educational grant from AstraZeneca.

+From the series Using Mechanism of Action to Choose Medications for Treatment-Resistant Depression

Supported by an educational grant from Otsuka America Pharmaceutical, Inc.

+From the series Criminal Forensic Psychiatry

Independently developed by the CME Institute of Physicians Postgraduate Press, Inc.

+From the series Cognition in the Depressed Patient

Supported by an educational grant from Takeda Pharmaceuticals International, Inc., U.S. Region and Lundbeck.

+From the series Understanding and Coping With Binge Eating Disorder: The Patient’s Perspective

Supported by an educational grant from Shire.

+From the series Overcoming Challenges in the Diagnosis and Management of ADHD in African American Adults

Supported by an educational grant from Shire.

+From the series Cause and Effect in Bipolar Depression: Misdiagnosis Leads to Inappropriate Treatment, Clinical Complications, and Adverse Outcomes

Supported by educational grants from Sunovion Pharmaceuticals and Supernus Pharmaceuticals.

+From the series New Strategies in Sleep

Supported by an educational grant from Merck & Co.

+From the series Challenges in the Recognition and Management of ADHD in Hispanic Adults in the United States

Supported by an educational grant from Shire.

+From the series Making Connections Between Science and Symptoms in Schizophrenia

Supported by an educational grant from Genentech.

+From the series Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder

Independently developed by the CME Institute of Physicians Postgraduate Press, Inc.

+From the series Treating and Caring for the Patient With Moderate-to-Severe Alzheimer's Disease

Supported by an educational grant from Forest Laboratories, Inc.

+From the series The Impact of Oral Medications on the Treatment of Multiple Sclerosis

Supported by an educational grant from Genzyme, a Sanofi Company, and Novartis Pharmaceuticals Corporation.

+From the series Improving Depression Outcomes by Providing Safe and Effective Care in the Rural Setting

Supported by an educational grant from Forest Research Institute, a subsidiary of Forest Laboratories, Inc.

+From the series Depression: Addressing Partial Response After First-Line Antidepressant Treatment

Supported by an educational grant from Lilly USA, LLC.

+From the series Controversies in the Psychopharmacology of Bipolar Disorder

Supported by an educational grant from Sunovion Pharmaceuticals, Inc.

+From the series Appropriate Management of Multiple Sclerosis in Primary Care

Supported by educational grants from EMD Serono and Genzyme, a Sanofi Company.

+From the series Update on Best Practices for Managing Bipolar Depression

Supported by an educational grant from Sunovion Pharmaceuticals, Inc.

+From the series Measurement-Based Strategies to Assess and Manage Schizophrenia   

Supported by an educational grant from Genentech.

+From the series Benefits and Barriers to Using Long-Acting Injectable Antipsychotics in Schizophrenia

Supported by an educational grant from from Otsuka America Pharmaceutical, Inc. and Lundbeck.

+From the series Improving the Diagnosis and Management of Depression in Bipolar Disorder

Supported by an educational grant from Teva Pharmaceuticals.

+From the series Improving the Differential Diagnosis and Treatment of Bipolar Depression in Primary Care

Supported by an educational grant from Sunovion Pharmaceuticals.

+From the series Update on Treatment-Resistant Depression: Translating Clinical Science Into Effective Therapies

Supported by an educational grant from Otsuka America Pharmaceutical, Inc.

+From the series Restless Legs Syndrome: Recognition, Diagnosis, and Treatment of a Common Sleep Disorder

Supported by an educational grant from UCB, Inc.

+From the series Treatment of Depression in Primary Care: Using Tools to Improve Outcomes

Supported by an educational grant from Forest Laboratories, Inc.

+From the series Depression: Managing the Full Range of Symptoms to Achieve Lasting Remission

Supported by an educational grant from Takeda Pharmaceuticals International, Inc., US Region and Lundbeck.

+From the series Working Together to Restore Mental Well-Being and Address Domestic Violence Among Veterans: A Call To Action

Supported by an educational grant from Blue Shield of California Foundation.

+From the series Complicated OCD: Issues of Comorbidity and Clinical Challenges

Independently developed by the CME Institute of Physicians Postgraduate Press, Inc., and the Lindner Center of HOPE

+From the series Understanding the Sleep-Wake Cycle: Sleep, Insomnia, and the Orexin System

Supported by an educational grant from Merck & Co., Inc.

+From the series Assessing and Managing Pain and Major Depression With Medical Comorbidities

Supported by an educational grant from Lilly.

+From the series Schizophrenia: Using Long-Acting Injectable Antipsychotics to Improve Treatment Adherence

Supported by an educational grant from Otsuka America Pharmaceutical, Inc.

+From the series The Effects of the Affordable Care Act on the Practice of Psychiatry

Independently developed by the CME Institute of Physicians Postgraduate Press, Inc.

+From the series ADHD in College, Phase II: Managing the Risk of Misuse, Abuse, and Diversion

Supported by an independent medical education grant from Shire.

+From the series Caring for Returning Veterans: Meeting Mental Health Needs

Independently developed by the CME Institute of Physicians Postgraduate Press, Inc.

+From the series Alzheimer's Disease: The Importance of Early Diagnosis and Appropriate Management

Supported by an educational grant from Lilly USA, LLC.

+From the series Military- and Sports-Related Mild Traumatic Brain Injury: Clinical Presentation, Management, and Long-Term Consequences

Independently developed by the CME Institute of Physicians Postgraduate Press, Inc.

+From the series Expired Other

+From the series Negative Symptoms in Schizophrenia: Treatment Gaps and Unmet Needs

Supported by an educational grant from Genentech

+From the series The Effect of Marijuana Use on the Risk for Schizophrenia

Independently developed by the CME Institute of Physicians Postgraduate Press, Inc.

+From the series Depression, Pain, and Comorbid Medical Conditions

Supported by an educational grant from Lilly USA, LLC.

+From the series Improving Outcomes in Multiple Sclerosis Through Early Diagnosis and Effective Management

Supported by an educational grant from Pfizer.

+From the series A Fresh Look at Monoamine Oxidase Inhibitors for Depression

Supported by an educational grant from Mylan Specialty L.P. (formerly known as Dey Pharma, L.P.)

+From the series NCDEU Poster Session 2012

+From the series New Treatment Approaches for Major Depressive Disorder  

Supported by an educational grant from Forest Laboratories.

+From the series Schizophrenia: When First-Line Treatment Fails

Supported by an educational grant from Teva.

+From the series Diagnosing and Managing Patients With Dementia

Supported by an educational grant from Pfizer.

+From the series ADHD in College: Seeking and Receiving Care During the Transition From Child to Adult

Supported by an independent medical educational grant from Shire

+From the series Overview of Current Issues in the Management of Multiple Sclerosis

Independently developed by the CME Institute of Physicians Postgraduate Press, Inc.

+From the series International Consensus Group on Depression Prevention in Bipolar Disorder

Supported by an educational grant from GlaxoSmithKline.

+From the series Alzheimer's Disease: Implications of the Updated Diagnostic and Research Criteria

Independently developed by The CME Institute of Physicians Postgraduate Press, Inc.

+From the series Fibromyalgia: Creating a Patient-Centered Diagnostic and Therapeutic Roadmap

Supported by an educational grant from Pfizer.

+From the series 2011 ICBD Conference Coverage: Practical Applications of New Research in Bipolar Disorder

Supported by an educational grant from Bristol-Myers Squibb.

+From the series Evidence for Using L-Methylfolate Combined With Antidepressants in MDD

Supported by an educational grant from Pamlab, LLC.

+From the series Depression: When Initial Therapy Fails

Supported by an educational grant from AstraZeneca.

+From the series Using Diagnostic and Assessment Tools for Adolescents With ADHD

Supported by an educational grant from Shire.

+From the series Using Moderator-Based Algorithms  and Electronic Medical Records  to Achieve Optimal Outcomes in Depression

Jointly sponsored by Vanderbilt School of Medicine and the CME Institute of Physicians Postgraduate Press, Inc. Vanderbilt School of Medicine and the CME Institute of Physicians Postgraduate Press, Inc., express appreciation to the following company for i

+From the series The Current Crisis of Confidence in Antidepressants

Independently developed by the CME Institute of Physicians Postgraduate Press, Inc.

+From the series New Approaches to Managing Schizoaffective Disorder From Diagnosis to Treatment

Supported by an educational grant from Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. administered by Ortho-McNeil Janssen Scientific Affairs, LLC.

+From the series Looking Past First-Line Therapy for Major Depressive Disorder

Supported by an educational grant from AstraZeneca

+From the series Considerations in Managing Schizophrenia in Adolescents

Supported by an educational grant from Eli Lilly and Company.

+From the series Challenges in the Long-Term Treatment of Schizophrenia

Supported by an educational grant from Eli Lilly and Company.

+From the series Improving Outcomes in Bipolar Disorder: From Early Recognition and Treatment to Remission

Supported by an educational grant from Eli Lilly and Company.

+From the series Strategies for Selecting Treatment and Mitigating Risk in Patients With Chronic Pain

Supported by an unrestricted educational grant from Purdue Pharma LP.

+From the series Strategies for the Long-Term Treatment of Bipolar Disorder in Children and Adults

Supported by an educational grant from Pfizer.

+From the series Improving the Recognition and Treatment of Bipolar Disorder in Primary Care

Supported by an educational grant from AstraZeneca

+From the series Improving Executive Function in Adults With ADHD

Supported by an educational grant from Eli Lilly and Company.

+From the series Improving Outcomes in Depression

Supported by an educational grant from Eli Lilly and Company.

+From the series International Consensus Group on Depression

Supported by an educational grant from GlaxoSmithKline.

+From the series Tackling Partial Remission to Depression Treatment

Supported by an educational grant from Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

+From the series The Use of Complementary and Alternative Medicines to Achieve Remission in Major Depressive Disorder

Supported by an educational grant from Pamlab, LLC.

+From the series What Is Bipolar Disorder?

These activities are part of the Bipolar Disorder Unit, which was supported by an educational grant from Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

+From the series An Introduction to the Clinical Correlates of Disrupted Slow-Wave Sleep

Supported by an educational grant from sanofi-aventis.

+From the series Following Up on The Expert Consensus Guidelines for Geriatric Depression

Supported by an educational grant from Eli Lilly and Company.

+From the series Depression in Latinos: A Focus on Overcoming Barriers

Supported by an educational grant from Wyeth.

+From the series Bipolar Disorder in Children and Adolescents

Supported by an educational grant from Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

+From the series Definition and Management of Suicidality in Psychiatric Patients

Independently developed by the CME Institute of Physicians Postgraduate Press, Inc.

+From the series Balancing the Equation: Managing Medical Comorbidities in Patients With Severe Mental Illness

Supported by an educational grant from Pfizer Inc.

+From the series Expired Case & Comment

+From the series Maintenance of Certification in Psychiatry

Independently developed by the CME Institute of Physicians Postgraduate Press, Inc.

+From the series Bipolar Depression

Supported by an educational grant from Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

+From the series What Is Depression?

Independently developed by the CME Institute of Physicians Postgraduate Press, Inc., and the American Society of Clinical Psychopharmacology.

+From the series MDD in Women: Focus on Reproductive Events

Independently developed by the CME Institute of Physicians Postgraduate Press, Inc., and the American Society of Clinical Psychopharmacology

+From the series Using Atypical Antipsychotics to Optimize the Clinical Management of Patients With Mental Illnesses

Supported by an educational grant to i3 CME from Bristol-Myers Squibb and Otsuka America Pharmaceutical, Inc.

+From the series Depression in the Elderly

Independently developed by the CME Institute of Physicians Postgraduate Press, Inc., and the American Society of Clinical Psychopharmacology.

+From the series Preventing Clinical Deterioration in the Course of Schizophrenia: The Potential for Neuroprotection

Supported by an educational grant from Eli Lilly and Company.

+From the series ADHD and Comorbid Disorders in Adults

Supported by an educational grant from Eli Lilly and Company.

+From the series Major Depressive Disorder

These activities are part of the Depression Unit, which is supported by educational grants from Eli Lilly and Company and Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

+From the series Easing the Burden of Treatment-Resistant Depression

Supported by an educational grant from Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

+From the series Depression and Pain

Supported by an educational grant from Eli Lilly and Company.

+From the series Depression, Pain, and Physical Symptoms

These activities are part of the Depression Unit, which is supported by educational grants from Eli Lilly and Company and Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

+From the series Easing the Burden of Bipolar Disorder: From Urgent Situations to Remission

Supported by an educational from Eli Lilly and Company.

+From the series Understanding Fibromyalgia and Its Related Disorders

Supported by an educational grant from Eli Lilly and Company.

+From the series Translating the Psychopharmacology of Antipsychotics to Individualized Treatment for Severe Mental Illness: A Roadmap

All content was developed by the Expert Knowledge Systems division of Comprehensive Neuroscience, Inc., and the CME Institute of Physicians Postgraduate Press, Inc., pursuant to an educational from Bristol-Myers Squibb.

+From the series Clinical Insights Into Pharmacogenetics and Schizophrenia

Supported by an educational grant from Vanda Pharmaceuticals, Inc.

+From the series Pain and the Brain

Supported by an educational grant from Eli Lilly and Company.

+From the series The Use of Atypical Antipsychotics in Pediatric Psychiatric Disorders

Supported by an educational grant from Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

+From the series Influencers of Treatment Success in Schizophrenia and Bipolar Disorder

This Supplement was independentaly developed by CME Outfitters and the CME Institute of Physicians Postgraduate Press, Inc., pursuant to an educational grant from Bristol-Myers Squibb and Otsuka Pharmaceutical.

+From the series Maximizing Efficacy of Antidepressants Beyond Selective Serotonin Reuptake Inhibitors

Supported by an educational grant from GlaxoSmithKline Services Unlimited.

+From the series Conference Coverage: 20th European College of Neuropsychopharmacology (ECNP) Congress

Supported by an educational grant from Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd.

+From the series Raising the Bar in Schizophrenia by Treating to Remission

Supported by an educational grant from Janssen LP administered by Ortho-McNeil Janssen Scientific Affairs, L.L.C.

+From the series Diagnosis and Treatment Strategies for Mixed Episodes in Bipolar Disorder

Supported by an educational grant from Eli Lilly and Company.

+From the series Presentations From the Seventh International Conference on Bipolar Disorder

Supported by educational grants from Eli Lilly and Company, Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc, and Pfizer Inc.

+From the series Narcolepsy and Excessive Daytime Sleepiness: From the Bench to the Bedside

This activity was independently developed by The Chatham Institute pursuant to an educational grant from Jazz Pharmaceuticals, Inc. The CME Institute of Physicians Postgraduate Press, Inc., an ACCME accredited provider, was the joint sponsor.

+From the series Atypical Depression: Management Challenges and New Treatment Advances

Supported by an educational grant from Bristol-Myers Squibb Company.

+From the series Cognitive Impairment Associated With Depression in the Elderly

Supported by an educational grant from Forest Pharmaceuticals, Inc.

+From the series Managing Bipolar Disorder From Urgent Situations to Maintenance Therapy

Supported by an educational grant from Eli Lilly and Company.

+From the series Weighing the Evidence: Weight Management Insights for Treating Major Mental Illness

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Postgraduate Institute for Medicine, ACCELMED, and the CME Institute of Physicians Postgraduate Press, Inc. This activity was supported by an educational grant from Eli Lilly and Company.

+From the series ADHD and Comorbid Substance Use Disorder

Supported by an educational grant from Shire Pharmaceuticals Inc.

+From the series Mixed Depression in Bipolar Disorders: Diagnosis and Treatment Strategies

Supported by an educational grant from Eli Lilly and Company.

+From the series The Role of Folate in Depression and Dementia

Supported by an educational grant from PamLab, L.L.C.

+From the series Strategies to Integrate Physical Health Care Into Mental Health

These activities were independently developed by the CME Institute of Physicians Postgraduate Press, Inc., and Letters & Sciences pursuant to an educational grant from Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

+From the series Special Issues Related to the Management of Bipolar Disorder in Women: Tolerability of Treatment

Supported by an educational grant from GlaxoSmithKline.

+From the series Translating Evidence on Depression and Physical Symptoms into Effective Clinical Practice

Supported by an educational grant from Eli Lilly and Company.

+From the series Distance Rounds

These activities were independently developed by Physicians Postgraduate Press, Inc., and the American Society of Clinical Psychopharmacology.

+From the series Monoamine Oxidase Inhibitors Revisited: Their Role in Depressive Disorders

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of CME Outfitters and the CME Institute of Physicians Postgraduate Press, Inc. This activity was supported by an educational grant from Bristol-Myers Squibb Company.

+From the series The Art and Science of Switching Antipsychotic Medications

These activities were independently developed by the CME Institute of Physicians Postgraduate Press, Inc., and SciMed pursuant to an educational grant from Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.

+From the series Preventing Recurrent Depression: Long-Term Treatment for Major Depressive Disorder

These activities were independently developed by the University of California, Irvine School of Medicine and the CME Institute of Physicians Postgraduate Press, Inc., pursuant to an educational grant from Wyeth Pharmaceuticals.

+From the series Understanding Neuronal Pathways: Novel Targets for the Management of Insomnia

This activity was supported by an educational grant from Merck and Lundbeck. Editorial assistance and honoraria were provided by Physicians Postgraduate Press, Inc., and SciMed.

+From the series Managing ADHD in Children, Adolescents, and Adults With Comorbid Anxiety

Supported by an educational grant from Eli Lilly and Company.

+From the series Transcranial Magnetic Stimulation: Potential New Treatment for Resistant Depression

Supported by an educational grant from Neuronetics, Inc.

+From the series Evaluating the Evidence: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and Beyond

This activity was independently developed by the CME Institute of Physicians Postgraduate Press, Inc., and Health and Wellness Education Partners pursuant to an educational grant from Pfizer Inc and additional financial support from HWP Publishing.

+From the series Practical Applications of Recent Antipsychotic Effectiveness Data

Supported by an educational grant from Eli Lilly and Company.

+From the series ADHD: Applying Practice Guidelines to Improve Patient Outcome and Executive Function

Supported by an educational grant from McNeil Pharmaceuticals.

+From the series Practical Pharmacotherapeutic Management Strategies for Patients With Alcohol Dependence

This activity was independently developed by the CME Institute of Physicians Postgraduate Press, Inc., and Fusion Medical Education pursuant to an educational grant from Alkermes, Inc. and Cephalon, Inc.

+From the series New Developments in Addiction Treatment

Supported by an educational grant from Cephalon, Inc.

+From the series Psychiatry in Brief: Insomnia and Emerging Therapies: Treating the Whole Patient

Supported by an educational grant from sanofi-aventis U.S.

+From the series Improving Cognitive Function and Functional Outcome in Severe Mental Illness

Supported by an educational grant from Bristol-Myers Squibb Company.

+From the series Social Anxiety Disorder: Diagnosis, Outcome, Mechanisms, and Management

This activity was independently developed by the CME Institute of Physicians Postgraduate Press, Inc., and Imprint Science pursuant to an educational grant from Forest Laboratories, Inc.

+From the series Recent Advances in the Treatment of Depression in the Presence of Physical Symptoms

Supported by an educational grant from Eli Lilly and Company.

+From the series Managing Patients With Vascular Disease and Depression

Supported by an educational grant from Forest Laboratories, Inc.

+From the series Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD): A Clinical View

Supported by an educational grant from GlaxoSmithKline.

+From the series New Developments in the Treatment of Attention-Deficit/Hyperactivity Disorder

Supported by an educational grant from Cephalon, Inc.

+From the series The Challenges of Dual Diagnosis: Managing Substance Abuse in Severe Mental Illness

Supported by an educational grant from AstraZeneca Pharamaceuticals LP.

+From the series Emerging Therapies for Bipolar Depression

Supported by an educational grant from Cyberonics, Inc.

+From the series The Role of Dopamine and Norepinephrine in Depression and Antidepressant Treatment

Supported by an educational grant from GlaxoSmithKline.

+From the series Managing Nonadherence in Schizophrenia: The Role of Long-Acting Agents

Supported by an educational grant from Janssen Medical Affairs, L.L.C.

+From the series Distance Rounds

These activities were independently developed by Physicians Postgraduate Press, Inc., and the American Society of Clinical Psychopharmacology.

+From the series Identifying and Managing Depression in the Medical Patient

Supported by an educational grant from Eli Lilly and Company.

+From the series Review of the Pharmacologic Management of Depression

Supported by an educational grant from GalxoSmithKline.

+From the series Bipolar Reports

Supported by an educational grant from GlaxoSmithKline.

+From the series After the Tsunami: Mental Health Challenges to the Community for Today and Tomorrow

This activity was independtly developed by the CME Institute of Physicians Postgraduate Press, Inc., and PPS International Communications pursuant to an educational grant from Pfizer Inc.

+From the series Sleep: New Frontiers in Psychiatry and Primary Care

Supported by an educational grant from Takeda Pharmaceuticals North America, Inc.

+From the series The Recognition and Management of Bipolar Disorder With Comorbid Anxiety

Supported by an educational grant from Janssen Medical Affairs, L.L.C.

+From the series Focus on Bipolar Disorder Treatment

Supported by an educational grant from GlaxoSmithKline.

+From the series Management of Autism and Its Related Disorders

Supported by an educational grant from Janssen Medical Affairs, L.L.C.